Advertisement
Canada markets close in 5 hours 51 minutes

  • S&P/TSX

    21,703.86
    +47.81 (+0.22%)
     

  • S&P 500

    5,027.11
    +4.90 (+0.10%)
     

  • DOW

    37,940.66
    +187.35 (+0.50%)
     

  • CAD/USD

    0.7265
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    82.89
    +0.20 (+0.24%)
     

  • Bitcoin CAD

    86,634.24
    +1,101.14 (+1.29%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,396.00
    +7.60 (+0.32%)
     

  • RUSSELL 2000

    1,949.51
    +1.56 (+0.08%)
     

  • 10-Yr Bond

    4.6270
    +0.0420 (+0.92%)
     

  • NASDAQ

    15,662.35
    -21.03 (-0.13%)
     

  • VOLATILITY

    18.07
    -0.14 (-0.77%)
     

  • FTSE

    7,857.64
    +9.65 (+0.12%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • CAD/EUR

    0.6815
    +0.0013 (+0.19%)
     
MARKETS LIVE BLOG:

STOCKS RISE AT OPEN AS TECHS REVIVE, WITH NETFLIX EARNINGS ON TAP

U.S. bond yields continue to slip away from recent five-month highs, easing pressure on stocks

U.S. CDC sees lower rates of allergic reaction after Pfizer vaccine

Reuters
·1 min read

NEW YORK, Jan 27 (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) said on Wednesday it is observing a lower rate of severe allergic reactions in people in the United States who have received Pfizer Inc and BioNTech SE's COVID-19 vaccine.

The CDC said that through Jan. 18, there were 50 cases of anaphylaxis reported in recipients of the vaccine. That implies a rate of about 5 per million doses administered, down from its previously reported rate of 11.1 per million doses administered through Dec. 23.

It reported 21 cases of anaphylaxis after Moderna Inc's COVID-19 vaccine was administered. That implies a rate of 2.8 cases per million doses, up slightly from the previously reported rate of 2.5 per million doses, based on data through Jan. 10. (Reporting by Michael Erman Editing by Chizu Nomiyama)